APA (7th ed.) Citation

Canino, F., Barbolini, M., De Giorgi, U., Fontana, T., Gaspari, V., Gianni, C., . . . Antonelli, G. (2024). Safety and efficacy analysis of neoadjuvant pertuzumab, trastuzumab and standard chemotherapy for HER2–positive early breast cancer: Real–world data from NeoPowER study. BMC Cancer, 24(1), 1. https://doi.org/10.1186/s12885-024-12506-0

Chicago Style (17th ed.) Citation

Canino, Fabio, et al. "Safety and Efficacy Analysis of Neoadjuvant Pertuzumab, Trastuzumab and Standard Chemotherapy for HER2–positive Early Breast Cancer: Real–world Data from NeoPowER Study." BMC Cancer 24, no. 1 (2024): 1. https://doi.org/10.1186/s12885-024-12506-0.

MLA (9th ed.) Citation

Canino, Fabio, et al. "Safety and Efficacy Analysis of Neoadjuvant Pertuzumab, Trastuzumab and Standard Chemotherapy for HER2–positive Early Breast Cancer: Real–world Data from NeoPowER Study." BMC Cancer, vol. 24, no. 1, 2024, p. 1, https://doi.org/10.1186/s12885-024-12506-0.